Update: Characteristics of a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, August 2019-January 2020.
Journal
MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429
Informations de publication
Date de publication:
24 Jan 2020
24 Jan 2020
Historique:
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
25
1
2020
Statut:
epublish
Résumé
Since August 2019, CDC, the Food and Drug Administration (FDA), state and local health departments, and public health and clinical stakeholders have been investigating a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). This report updates patient demographic characteristics, self-reported substance use, and hospitalization dates for EVALI patients reported to CDC by states, as well as the distribution of emergency department (ED) visits related to e-cigarette, or vaping, products analyzed through the National Syndromic Surveillance Program (NSSP). As of January 14, 2020, a total of 2,668 hospitalized EVALI cases had been reported to CDC. Median patient age was 24 years, and 66% were male. Overall, 82% of EVALI patients reported using any tetrahydrocannabinol (THC)-containing e-cigarette, or vaping, product (including 33% with exclusive THC-containing product use), and 57% of EVALI patients reported using any nicotine-containing product (including 14% with exclusive nicotine-containing product use). Syndromic surveillance indicates that ED visits related to e-cigarette, or vaping, products continue to decline after sharply increasing in August 2019 and peaking in September 2019. Clinicians and public health practitioners should remain vigilant for new EVALI cases. CDC recommends that persons not use THC-containing e-cigarette, or vaping, products, especially those acquired from informal sources such as friends, family members, or from in-person or online dealers. Vitamin E acetate is strongly linked to the EVALI outbreak and should not be added to any e-cigarette, or vaping, products (2). However, evidence is not sufficient to rule out the contribution of other chemicals of concern, including chemicals in either THC- or non-THC-containing products, in some reported EVALI cases.
Identifiants
pubmed: 31971931
doi: 10.15585/mmwr.mm6903e2
pmc: PMC7367698
doi:
Substances chimiques
Vitamin E
1406-18-4
Dronabinol
7J8897W37S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-94Investigateurs
Amena Abbas
(A)
Adebola Adebayo
(A)
Sukhshant Atti
(S)
Tegan Boehmer
(T)
Elizabeth Carter
(E)
Gyan Chandra
(G)
Lindsay Eckhaus
(L)
Janet Hamilton
(J)
Mia Israel
(M)
Zheng Li
(Z)
Caitlin Loretan
(C)
Ruth Lynfield
(R)
Nisha Nataraj
(N)
Mary Pomeroy
(M)
Caroline Schrodt
(C)
Herschel Smith
(H)
Kimberly Thomas
(K)
Angela Werner
(A)
Déclaration de conflit d'intérêts
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Références
MMWR Morb Mortal Wkly Rep. 2019 Nov 01;68(43):985-989
pubmed: 31671085
MMWR Morb Mortal Wkly Rep. 2020 Jan 17;69(2):44-49
pubmed: 31945038
N Engl J Med. 2020 Feb 20;382(8):697-705
pubmed: 31860793
MMWR Morb Mortal Wkly Rep. 2019 Nov 29;68(47):1096-1100
pubmed: 31774740
N Engl J Med. 2020 Feb 20;382(8):766-772
pubmed: 31860794
MMWR Morb Mortal Wkly Rep. 2020 Jan 24;69(3):84-89
pubmed: 31971930
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1076-1080
pubmed: 31751326